[Nitric oxide availability in cerebral microangiopathy].
Larisa A DobryninaA A ShabalinaK V ShamtievaElena I KremnevaMaryam R ZabitovaA G BurmakA A ByrochkinaYu I AkhmetshinaElena V GnedovskayaMarina V KrotenkovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
The prolonged rate of erythrocyte disaggregation in cSVD patients after incubation with L-arginine indicates the risk for disease progression due to decreased NO bioavailability/disruption of the functional L-arginine-eNOS-NO system. This test can be used to assess individual NO bioavailability and potentially identify indications for modifying therapy with NO donors such as L-arginine. Clinical trials are needed to standardize and evaluate the efficacy of NO donor therapy in patients with cSVD and CI.